Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06355934 · ClinicalTrials.gov registry record

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

A clinical trial of ATTR Amyloidosis, sponsored by AstraZeneca.

Recruiting
Registry status
52,121
Enrollment target
20
Study locations

NCT06355934 is a study of ATTR Amyloidosis that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 52,121 participants. The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06355934, a study of ATTR Amyloidosis, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
52,121 participants
Enrollment target
20
Study locations

Study Summary

The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.

Conditions Studied

Interventions

  • OTHER no intervention

Study Locations (20)

Other

  • Research Site - Beijing
  • Research Site - Changsha
  • Research Site - Chengdu
  • Research Site - Guangzhou
  • Research Site - Wuhan
  • Research Site - Horsens
  • Research Site - Berlin
  • Research Site - Tokyo
  • Research Site - Lisbon
  • Research Site - Porto
  • Research Site - A Coruña
  • Research Site - Barcelona
  • Research Site - Bilbao
  • Research Site - El Palmar
  • Research Site - Huelva
  • Research Site - Las Palmas de Gran Canaria
  • Research Site - Madrid
  • Research Site - Majadahonda

Minnesota

  • Research Site - Eden Prairie

Alberta

  • Research Site - Calgary

Trial Details

FieldValue
Enrollment Target 52,121 participants
Start Date 2023-08-21
Est. Completion 2026-09-30

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT06355934

The ClinicalTrials.gov registry entry for NCT06355934 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 52,121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with ATTR Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which no intervention is the first listed.

NCT06355934 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, Minnesota, Alberta.

Frequently Asked Questions

What is clinical trial NCT06355934 about?

NCT06355934 is a clinical study titled "OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis". The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropa...

What is the current status of trial NCT06355934?

This trial is currently recruiting. The enrollment target is 52,121 participants. The study started on 2023-08-21. Estimated completion is 2026-09-30.

What conditions does trial NCT06355934 study?

This clinical trial studies the following conditions: ATTR Amyloidosis.

What interventions are being tested in trial NCT06355934?

The interventions under investigation include: no intervention (OTHER).

Who is sponsoring clinical trial NCT06355934?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06355934 being conducted?

This trial has 20 study locations across Minnesota, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ATTR Amyloidosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.